Exploring New 5-Nitroimidazole Derivatives As Potent Acetylcholinesterase and Butyrylcholinesterase Enzyme Inhibitors.

5-nitroimidazole Acetylcholinesterase Alzheimer's disease butyrylcholinesterase molecular docking

Journal

Chemistry & biodiversity
ISSN: 1612-1880
Titre abrégé: Chem Biodivers
Pays: Switzerland
ID NLM: 101197449

Informations de publication

Date de publication:
26 Jun 2024
Historique:
revised: 21 06 2024
received: 14 04 2024
accepted: 24 06 2024
medline: 26 6 2024
pubmed: 26 6 2024
entrez: 26 6 2024
Statut: aheadofprint

Résumé

Discovering new compounds capable of inhibiting physiologically and metabolically significant drug targets or enzymes is of paramount importance in biological chemistry. With this aim, new 5-nitroimidazole derivatives (1-4) were designed and synthesized, and their inhibitory activities against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) were discovered using acetyl (butyryl) thiocholine and Ellman's reagents for spectrophotometric assay. The inhibitory profiles of the synthesized compounds were assessed by comparing their IC50 and Ki values. Results demonstrate significant inhibitory activity of all synthesized compounds against both AChE and BuChE compared to the reference compound, donepezil. Notably, compound 4 exhibited dual inhibition of these enzymes, showing the highest activity against Electrophorus electricus AChE (EeAChE) with a Ki value of 0.024±0.009 nM and against equine BuChE (eqBuChE) with a Ki value of 0.087±0.017 nM. Furthermore, molecular modeling was conducted to study the interaction modes of the most potent compound (4) and donepezil in the active site of their related enzymes' crystal structures (PDB ID: 4EY7 and 4BDS, respectively). Additionally, drug-likeness, ADME, and toxicity profiles of the compounds and metronidazole were predicted. The above results indicated that the dual inhibition of these enzymes is considered as a promising strategy for the treatment of neurological disorder especially Alzheimer's disease.

Identifiants

pubmed: 38924646
doi: 10.1002/cbdv.202400918
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e202400918

Informations de copyright

© 2024 Wiley‐VCH GmbH.

Auteurs

Sule Gursoy (S)

Erzincan University, Biochemistry, Yanlızbag Campus, 24002, Erzincan, TURKEY.

Doruk Satıcı (D)

Erzincan University, Biochemistry, Yalnızbag Campus, Erzincan, TURKEY.

Burak Kuzu (B)

Van Yuzuncu Yil University, Pharmaceutical Chemistry, Faculty of Pharmacy, Van, TURKEY.

Burcin Turkmenoglu (B)

Erzincan University, Analytical Chemistry, Yalnızbag Campus, Erzincan, TURKEY.

Esra Dilek (E)

Erzincan University, Biochemistry, Yalnızbag Campus, Erzincan, TURKEY.

Oztekin Algul (O)

Mersin University, Pharmaceutical Chemistry, Yenisehir Campus, Mersin, TURKEY.

Classifications MeSH